Pathway polygenic risk scores (pPRS) for the analysis of gene-environment interaction.

IF 3.7 2区 生物学 Q1 GENETICS & HEREDITY
PLoS Genetics Pub Date : 2025-08-05 eCollection Date: 2025-08-01 DOI:10.1371/journal.pgen.1011543
W James Gauderman, Yubo Fu, Bryan Queme, Eric Kawaguchi, Yinqiao Wang, John Morrison, Hermann Brenner, Andrew Chan, Stephen B Gruber, Temitope Keku, Li Li, Victor Moreno, Andrew J Pellatt, Ulrike Peters, N Jewel Samadder, Stephanie L Schmit, Cornelia M Ulrich, Caroline Um, Anna Wu, Juan Pablo Lewinger, David A Drew, Huaiyu Mi
{"title":"Pathway polygenic risk scores (pPRS) for the analysis of gene-environment interaction.","authors":"W James Gauderman, Yubo Fu, Bryan Queme, Eric Kawaguchi, Yinqiao Wang, John Morrison, Hermann Brenner, Andrew Chan, Stephen B Gruber, Temitope Keku, Li Li, Victor Moreno, Andrew J Pellatt, Ulrike Peters, N Jewel Samadder, Stephanie L Schmit, Cornelia M Ulrich, Caroline Um, Anna Wu, Juan Pablo Lewinger, David A Drew, Huaiyu Mi","doi":"10.1371/journal.pgen.1011543","DOIUrl":null,"url":null,"abstract":"<p><p>A polygenic risk score (PRS) is used to quantify the combined disease risk of many genetic variants. For complex human traits there is interest in determining whether the PRS modifies, i.e. interacts with, important environmental (E) risk factors. Detection of a PRS by environment (PRS x E) interaction may provide clues to underlying biology and can be useful in developing targeted prevention strategies for modifiable risk factors. The standard PRS may include a subset of variants that interact with E but a much larger subset of variants that affect disease without regard to E. This latter subset will dilute the underlying signal in former subset, leading to reduced power to detect PRS x E interaction. We explore the use of pathway-defined PRS (pPRS) scores, using state of the art tools to annotate subsets of variants to genomic pathways. We demonstrate via simulation that testing targeted pPRS x E interaction can yield substantially greater power than testing overall PRS x E interaction. We also analyze a large study (N = 78,253) of colorectal cancer (CRC) where E = non-steroidal anti-inflammatory drugs (NSAIDs), a well-established protective exposure. While no evidence of overall PRS x NSAIDs interaction (p = 0.41) is observed, a significant pPRS x NSAIDs interaction (p = 0.0003) is identified based on SNPs within the TGF-β/ gonadotropin releasing hormone receptor (GRHR) pathway. NSAIDS is protective (OR=0.84) for those at the 5th percentile of the TGF-β/GRHR pPRS (low genetic risk, OR), but significantly more protective (OR=0.70) for those at the 95th percentile (high genetic risk). From a biological perspective, this suggests that NSAIDs may act to reduce CRC risk specifically through genes in these pathways. From a population health perspective, our result suggests that focusing on genes within these pathways may be effective at identifying those for whom NSAIDs-based CRC-prevention efforts may be most effective.</p>","PeriodicalId":49007,"journal":{"name":"PLoS Genetics","volume":"21 8","pages":"e1011543"},"PeriodicalIF":3.7000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12352875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS Genetics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1371/journal.pgen.1011543","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

A polygenic risk score (PRS) is used to quantify the combined disease risk of many genetic variants. For complex human traits there is interest in determining whether the PRS modifies, i.e. interacts with, important environmental (E) risk factors. Detection of a PRS by environment (PRS x E) interaction may provide clues to underlying biology and can be useful in developing targeted prevention strategies for modifiable risk factors. The standard PRS may include a subset of variants that interact with E but a much larger subset of variants that affect disease without regard to E. This latter subset will dilute the underlying signal in former subset, leading to reduced power to detect PRS x E interaction. We explore the use of pathway-defined PRS (pPRS) scores, using state of the art tools to annotate subsets of variants to genomic pathways. We demonstrate via simulation that testing targeted pPRS x E interaction can yield substantially greater power than testing overall PRS x E interaction. We also analyze a large study (N = 78,253) of colorectal cancer (CRC) where E = non-steroidal anti-inflammatory drugs (NSAIDs), a well-established protective exposure. While no evidence of overall PRS x NSAIDs interaction (p = 0.41) is observed, a significant pPRS x NSAIDs interaction (p = 0.0003) is identified based on SNPs within the TGF-β/ gonadotropin releasing hormone receptor (GRHR) pathway. NSAIDS is protective (OR=0.84) for those at the 5th percentile of the TGF-β/GRHR pPRS (low genetic risk, OR), but significantly more protective (OR=0.70) for those at the 95th percentile (high genetic risk). From a biological perspective, this suggests that NSAIDs may act to reduce CRC risk specifically through genes in these pathways. From a population health perspective, our result suggests that focusing on genes within these pathways may be effective at identifying those for whom NSAIDs-based CRC-prevention efforts may be most effective.

途径多基因风险评分(Pathway polygenic risk score, pPRS)用于分析基因与环境的相互作用。
多基因风险评分(PRS)用于量化许多遗传变异的综合疾病风险。对于复杂的人类特征,有兴趣确定PRS是否改变,即与重要的环境(E)风险因素相互作用。通过环境(PRS x E)相互作用检测PRS可能为潜在的生物学提供线索,并可用于制定针对可改变风险因素的有针对性的预防策略。标准PRS可能包括与E相互作用的变体子集,但影响疾病而不考虑E的变体的更大子集。后一个子集将稀释前一个子集中的潜在信号,导致检测PRS x E相互作用的功率降低。我们探索了途径定义的PRS (pPRS)分数的使用,使用最先进的工具来注释基因组途径的变体子集。我们通过模拟证明,测试目标pPRS x E相互作用可以产生比测试整体PRS x E相互作用大得多的功率。我们还分析了一项关于结直肠癌(CRC)的大型研究(N = 78,253),其中E =非甾体抗炎药(NSAIDs),这是一种公认的保护性暴露。虽然没有观察到总体PRS与NSAIDs相互作用的证据(p = 0.41),但基于TGF-β/促性腺激素释放激素受体(GRHR)通路内的snp,确定了显著的pPRS与NSAIDs相互作用(p = 0.0003)。非甾体抗炎药对TGF-β/GRHR pPRS第5百分位(低遗传风险,OR)的患者具有保护作用(OR=0.84),但对第95百分位(高遗传风险)的患者具有更大的保护作用(OR=0.70)。从生物学角度来看,这表明非甾体抗炎药可能通过这些途径中的基因特异性地降低结直肠癌风险。从人群健康的角度来看,我们的结果表明,关注这些途径中的基因可能有效地识别那些基于非甾体抗炎药的crc预防工作可能最有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PLoS Genetics
PLoS Genetics GENETICS & HEREDITY-
自引率
2.20%
发文量
438
期刊介绍: PLOS Genetics is run by an international Editorial Board, headed by the Editors-in-Chief, Greg Barsh (HudsonAlpha Institute of Biotechnology, and Stanford University School of Medicine) and Greg Copenhaver (The University of North Carolina at Chapel Hill). Articles published in PLOS Genetics are archived in PubMed Central and cited in PubMed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信